We are live on ! Find out more
JP

John Paulson Paulson & Co

AUM $2.58B
1-Year Est. Return 68.51%
 

John Paulson is the founder of Paulson & Co., a firm that became world-famous for profits related to the 2007–2008 housing and credit crisis. Beyond that landmark trade, the firm has pursued merger arbitrage, event-driven, and opportunistic credit and equity strategies. Paulson remains one of the most recognized names in modern hedge fund history.

This Fund
S&P 500
This Quarter Est. Return
+4.33%
1 Year Est. Return
+68.51%
3 Year Est. Return
+251.48%
5 Year Est. Return
+229.81%
10 Year Est. Return
+881.28%
AUM
$7.53B
AUM Growth
-$400M
Cap. Flow
-$537M
Cap. Flow %
-7.12%
Top 10 Hldgs %
58.97%
Holding
128
New
26
Increased
14
Reduced
35
Closed
30

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$255M
2
DISH
DISH Network Corp.
DISH
+$213M
3
MJN
Mead Johnson Nutrition Company
MJN
+$94.9M
4
NXPI icon
NXP Semiconductors
NXPI
+$76.8M
5
BKD icon
Brookdale Senior Living
BKD
+$71.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$168M
2
AGN
Allergan plc
AGN
+$143M
3
STAY
Extended Stay America, Inc. Paired Share Unit
STAY
+$142M
4
VTRS icon
Viatris
VTRS
+$134M
5
HAR
Harman International Industries
HAR
+$94.9M

Sector Composition

Rank Sector Weight
1 Healthcare 49.18%
2 Communication Services 12.37%
3 Consumer Discretionary 11%
4 Materials 5.06%
5 Financials 3.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MON
76
DELISTED
Monsanto Co
MON
$4.02M 0.05%
+35,500
New +$3.93M
NVDQ
77
PUT
DELISTED
Novadaq Technologies Inc.
NVDQ
$3.9M 0.05%
500,000
– –
CYH icon
78
PUT
Community Health Systems
CYH
$424M
$3.02M 0.04%
340,000
-1,260,000
-79% -$9.83M
BCRX icon
79
CALL
BioCryst Pharmaceuticals
BCRX
$2.44B
$2.94M 0.04%
350,000
– –
DVAX
80
DELISTED
Dynavax Technologies
DVAX
$2.75M 0.04%
463,000
+289,000
+166% +$1.39M
HW
81
DELISTED
Headwaters Inc
HW
$2.35M 0.03%
+100,000
New +$2.33M
SRPT icon
82
Sarepta Therapeutics
SRPT
$1.98B
$2.31M 0.03%
+78,101
New +$2.42M
KTWO
83
DELISTED
K2M Group Holdings, Inc
KTWO
$1.98M 0.03%
+96,500
New +$1.98M
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$857M
$1.82M 0.02%
55,000
+16,230
+42% +$414K
INSM icon
85
Insmed
INSM
$27.5B
$1.58M 0.02%
90,000
-115,200
-56% -$1.78M
ALDR
86
DELISTED
Alder Biopharmaceuticals
ALDR
$1.54M 0.02%
74,000
– –
TRVN
87
DELISTED
Trevena, Inc.
TRVN
$1.5M 0.02%
+652
New +$2.22M
CNCE
88
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.2M 0.02%
+70,229
New +$842K
EDIT icon
89
Editas Medicine
EDIT
$478M
$1.12M 0.01%
+50,000
New +$1.04M
NTLA icon
90
Intellia Therapeutics
NTLA
$1.8B
$1.11M 0.01%
+78,600
New +$1.05M
CRSP icon
91
CRISPR Therapeutics
CRSP
$5.75B
$1.1M 0.01%
+50,500
New +$991K
TNDM icon
92
Tandem Diabetes Care
TNDM
$1.55B
$600K 0.01%
+50,000
New +$1.09M
PBYI icon
93
Puma Biotechnology
PBYI
$477M
$584K 0.01%
15,690
– –
MULE
94
DELISTED
MuleSoft, Inc.
MULE
$487K 0.01%
+20,000
New +$469K
ARDM
95
DELISTED
Aradigm Corp Common Stock
ARDM
$299K ﹤0.01%
192,727
– –
OSG
96
DELISTED
Overseas Shipholding Group Inc.
OSG
$174K ﹤0.01%
45,139
-26,463
-37% -$125K
ALNY icon
97
Alnylam Pharmaceuticals
ALNY
$31.6B
– –
-19,300
Closed -$723K
ARCC icon
98
Ares Capital
ARCC
$14.3B
$0 ﹤0.01%
+1
New +$17
BCRX icon
99
BioCryst Pharmaceuticals
BCRX
$2.44B
– –
-52,600
Closed -$366K
BSX icon
100
Boston Scientific
BSX
$73B
– –
-288,000
Closed -$6.23M
1 2 3
4
5

Similar funds

TC
Trilogy Capital Irvine, California $2.58B AUM 22.97% 1-Year Est. Return
RFP
Root Financial Partners Encinitas, California $2.57B AUM 21.7% 1-Year Est. Return
EV
Eclipse Ventures Palo Alto, California $2.57B AUM
MC
Moors & Cabot Boston, Massachusetts $2.57B AUM 37.84% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
CTA
Chesley Taft & Associates Chicago, Illinois $2.57B AUM 22.93% 1-Year Est. Return
VWM
Venturi Wealth Management Austin, Texas $2.58B AUM 41.25% 1-Year Est. Return

John Paulson's Q1 2017 Portfolio in Review

As of Q1 2017, John Paulson held 128 positions worth $7.53B, down 5% from $7.93B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

John Paulson withdrew a net $537M in Q1 2017, closing 30 positions and reducing 35 holdings. Its most notable exit was Harman International Industries, an estimated $94.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 53% a quarter earlier, followed by Communication Services and Consumer Discretionary.

Against the trend, John Paulson opened a new position in T-Mobile US worth $267M.

  • John Paulson's largest Q1 2017 buy was T-Mobile US: 4,140,100 shares worth $267M.
  • John Paulson added most to Mead Johnson Nutrition Company in Q1 2017, an estimated $94.9M increase.
  • John Paulson's biggest Q1 2017 reduction was Teva Pharmaceuticals, cutting an estimated $168M.
  • John Paulson fully exited Harman International Industries in Q1 2017, selling an estimated $94.9M.
  • John Paulson's ten largest holdings make up 59% of its $7.53B portfolio in Q1 2017.
  • John Paulson opened 26 new positions and closed 30 in Q1 2017.
  • John Paulson's portfolio value fell 5% quarter-over-quarter to $7.53B.

Based on Paulson & Co's 13F filing for Q1 2017, filed 15 May 2017.